GRAIL, Inc.
Key Metrics
- Previous Close
- $105.88
- 52-Week Range
- $41.50 – $166.48
- Market Cap
- $4.59B
- P/E (TTM)
- —
- EPS (TTM)
- -9.22
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.86
- PEG Ratio
- —
- Return on Equity
- -17.31%
- Return on Assets
- -12.97%
- Gross Margin
- 46.68%
- Operating Margin
- -332.04%
- Profit Margin
- -243.80%
- Current Ratio
- 8.93
- Debt/Equity
- 0.03
- Total Debt
- $85.85M
- Free Cash Flow
- $-112.64M
- Revenue Growth
- 3.70%
- Earnings Growth
- —
- Enterprise Value
- $3.89B
Market Snapshot
About
GRAIL, Inc. operates as a healthcare company focused on early cancer detection through blood testing technology. Headquartered in Menlo Park, California, the company develops and commercializes multi-cancer early detection tests using next-generation sequencing and machine learning algorithms. GRAIL's flagship product, Galleri, is a blood-based screening test designed to detect multiple types of cancer, many of which lack standard screening methods, often before symptoms appear. The test analyzes cell-free DNA in the bloodstream to identify cancer signals and predict the tissue of origin. The company was founded in 2016 as a spin-off from Illumina, Inc., which later reacquired GRAIL in 2021 for approximately $7.1 billion, though the acquisition faced significant regulatory scrutiny from the Federal Trade Commission and European Commission. In 2023, following an FTC order, Illumina began the process of divesting GRAIL as a separate entity. GRAIL employs over 1,500 people and operates laboratories and offices across the United States and internationally. The company targets healthcare providers, health systems, and self-pay consumers, positioning its technology as a complement to existing single-cancer screening programs. GRAIL continues to conduct clinical studies and pursue regulatory pathways while expanding commercial availability of its testing services in select markets.